|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DVL1 |
Gene summary for DVL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DVL1 | Gene ID | 1855 |
| Gene name | dishevelled segment polarity protein 1 | |
| Gene Alias | DRS2 | |
| Cytomap | 1p36.33 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | O14640 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1855 | DVL1 | LZE7T | Human | Esophagus | ESCC | 6.63e-03 | 1.01e-01 | 0.0667 |
| 1855 | DVL1 | LZE20T | Human | Esophagus | ESCC | 1.62e-04 | 1.24e-01 | 0.0662 |
| 1855 | DVL1 | LZE24T | Human | Esophagus | ESCC | 9.22e-08 | 1.31e-01 | 0.0596 |
| 1855 | DVL1 | LZE21T | Human | Esophagus | ESCC | 1.29e-02 | 8.75e-02 | 0.0655 |
| 1855 | DVL1 | P1T-E | Human | Esophagus | ESCC | 6.15e-09 | 3.04e-01 | 0.0875 |
| 1855 | DVL1 | P2T-E | Human | Esophagus | ESCC | 6.73e-07 | 1.08e-02 | 0.1177 |
| 1855 | DVL1 | P4T-E | Human | Esophagus | ESCC | 3.65e-15 | 1.72e-01 | 0.1323 |
| 1855 | DVL1 | P5T-E | Human | Esophagus | ESCC | 9.88e-08 | 9.93e-02 | 0.1327 |
| 1855 | DVL1 | P8T-E | Human | Esophagus | ESCC | 3.28e-16 | 3.73e-01 | 0.0889 |
| 1855 | DVL1 | P9T-E | Human | Esophagus | ESCC | 3.14e-07 | 4.08e-02 | 0.1131 |
| 1855 | DVL1 | P10T-E | Human | Esophagus | ESCC | 9.40e-14 | 8.76e-02 | 0.116 |
| 1855 | DVL1 | P11T-E | Human | Esophagus | ESCC | 3.28e-06 | 1.57e-01 | 0.1426 |
| 1855 | DVL1 | P12T-E | Human | Esophagus | ESCC | 1.69e-02 | -2.70e-02 | 0.1122 |
| 1855 | DVL1 | P15T-E | Human | Esophagus | ESCC | 4.33e-11 | 1.25e-01 | 0.1149 |
| 1855 | DVL1 | P16T-E | Human | Esophagus | ESCC | 1.69e-04 | -4.12e-02 | 0.1153 |
| 1855 | DVL1 | P17T-E | Human | Esophagus | ESCC | 7.08e-05 | 1.74e-01 | 0.1278 |
| 1855 | DVL1 | P20T-E | Human | Esophagus | ESCC | 5.31e-08 | 7.68e-02 | 0.1124 |
| 1855 | DVL1 | P21T-E | Human | Esophagus | ESCC | 1.83e-10 | 3.37e-01 | 0.1617 |
| 1855 | DVL1 | P22T-E | Human | Esophagus | ESCC | 2.81e-07 | -1.02e-03 | 0.1236 |
| 1855 | DVL1 | P23T-E | Human | Esophagus | ESCC | 6.07e-17 | 1.41e-01 | 0.108 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004573220 | Oral cavity | OSCC | positive regulation of protein catabolic process | 150/7305 | 231/18723 | 1.06e-15 | 7.64e-14 | 150 |
| GO:005109820 | Oral cavity | OSCC | regulation of binding | 212/7305 | 363/18723 | 3.88e-14 | 2.15e-12 | 212 |
| GO:005134820 | Oral cavity | OSCC | negative regulation of transferase activity | 165/7305 | 268/18723 | 5.02e-14 | 2.74e-12 | 165 |
| GO:001604917 | Oral cavity | OSCC | cell growth | 268/7305 | 482/18723 | 6.55e-14 | 3.51e-12 | 268 |
| GO:190336420 | Oral cavity | OSCC | positive regulation of cellular protein catabolic process | 106/7305 | 155/18723 | 1.07e-13 | 5.53e-12 | 106 |
| GO:001056320 | Oral cavity | OSCC | negative regulation of phosphorus metabolic process | 246/7305 | 442/18723 | 6.12e-13 | 2.89e-11 | 246 |
| GO:004593620 | Oral cavity | OSCC | negative regulation of phosphate metabolic process | 245/7305 | 441/18723 | 8.85e-13 | 4.09e-11 | 245 |
| GO:190180018 | Oral cavity | OSCC | positive regulation of proteasomal protein catabolic process | 82/7305 | 114/18723 | 9.33e-13 | 4.22e-11 | 82 |
| GO:190305217 | Oral cavity | OSCC | positive regulation of proteolysis involved in cellular protein catabolic process | 92/7305 | 133/18723 | 1.60e-12 | 6.90e-11 | 92 |
| GO:005082120 | Oral cavity | OSCC | protein stabilization | 122/7305 | 191/18723 | 2.69e-12 | 1.09e-10 | 122 |
| GO:004232619 | Oral cavity | OSCC | negative regulation of phosphorylation | 214/7305 | 385/18723 | 2.30e-11 | 7.74e-10 | 214 |
| GO:003243619 | Oral cavity | OSCC | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 66/7305 | 90/18723 | 3.76e-11 | 1.23e-09 | 66 |
| GO:200006020 | Oral cavity | OSCC | positive regulation of ubiquitin-dependent protein catabolic process | 75/7305 | 107/18723 | 6.67e-11 | 2.06e-09 | 75 |
| GO:004339318 | Oral cavity | OSCC | regulation of protein binding | 121/7305 | 196/18723 | 8.92e-11 | 2.73e-09 | 121 |
| GO:000193319 | Oral cavity | OSCC | negative regulation of protein phosphorylation | 191/7305 | 342/18723 | 1.58e-10 | 4.62e-09 | 191 |
| GO:003367317 | Oral cavity | OSCC | negative regulation of kinase activity | 140/7305 | 237/18723 | 2.74e-10 | 7.57e-09 | 140 |
| GO:000646918 | Oral cavity | OSCC | negative regulation of protein kinase activity | 127/7305 | 212/18723 | 5.21e-10 | 1.37e-08 | 127 |
| GO:001605510 | Oral cavity | OSCC | Wnt signaling pathway | 227/7305 | 444/18723 | 1.10e-07 | 1.87e-06 | 227 |
| GO:019873810 | Oral cavity | OSCC | cell-cell signaling by wnt | 227/7305 | 446/18723 | 1.75e-07 | 2.86e-06 | 227 |
| GO:002260419 | Oral cavity | OSCC | regulation of cell morphogenesis | 163/7305 | 309/18723 | 5.66e-07 | 8.19e-06 | 163 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05022210 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
| hsa05010210 | Esophagus | ESCC | Alzheimer disease | 263/4205 | 384/8465 | 1.80e-14 | 5.47e-13 | 2.80e-13 | 263 |
| hsa0516510 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
| hsa0522518 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
| hsa041505 | Esophagus | ESCC | mTOR signaling pathway | 98/4205 | 156/8465 | 5.81e-04 | 1.95e-03 | 9.97e-04 | 98 |
| hsa043306 | Esophagus | ESCC | Notch signaling pathway | 42/4205 | 62/8465 | 2.97e-03 | 7.97e-03 | 4.08e-03 | 42 |
| hsa0439018 | Esophagus | ESCC | Hippo signaling pathway | 92/4205 | 157/8465 | 1.46e-02 | 3.31e-02 | 1.69e-02 | 92 |
| hsa0502238 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
| hsa0501038 | Esophagus | ESCC | Alzheimer disease | 263/4205 | 384/8465 | 1.80e-14 | 5.47e-13 | 2.80e-13 | 263 |
| hsa0516515 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
| hsa0522519 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
| hsa0415013 | Esophagus | ESCC | mTOR signaling pathway | 98/4205 | 156/8465 | 5.81e-04 | 1.95e-03 | 9.97e-04 | 98 |
| hsa0433013 | Esophagus | ESCC | Notch signaling pathway | 42/4205 | 62/8465 | 2.97e-03 | 7.97e-03 | 4.08e-03 | 42 |
| hsa0439019 | Esophagus | ESCC | Hippo signaling pathway | 92/4205 | 157/8465 | 1.46e-02 | 3.31e-02 | 1.69e-02 | 92 |
| hsa0501022 | Liver | HCC | Alzheimer disease | 254/4020 | 384/8465 | 3.75e-14 | 8.97e-13 | 4.99e-13 | 254 |
| hsa0502222 | Liver | HCC | Pathways of neurodegeneration - multiple diseases | 298/4020 | 476/8465 | 6.59e-12 | 1.30e-10 | 7.22e-11 | 298 |
| hsa052258 | Liver | HCC | Hepatocellular carcinoma | 106/4020 | 168/8465 | 2.87e-05 | 1.85e-04 | 1.03e-04 | 106 |
| hsa051652 | Liver | HCC | Human papillomavirus infection | 188/4020 | 331/8465 | 3.34e-04 | 1.49e-03 | 8.29e-04 | 188 |
| hsa041502 | Liver | HCC | mTOR signaling pathway | 95/4020 | 156/8465 | 4.70e-04 | 1.99e-03 | 1.11e-03 | 95 |
| hsa0501032 | Liver | HCC | Alzheimer disease | 254/4020 | 384/8465 | 3.75e-14 | 8.97e-13 | 4.99e-13 | 254 |
| Page: 1 2 3 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DVL1 | SNV | Missense_Mutation | c.1625N>T | p.Tyr542Phe | p.Y542F | O14640 | protein_coding | tolerated(0.11) | possibly_damaging(0.596) | TCGA-A7-A0DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| DVL1 | SNV | Missense_Mutation | rs766988615 | c.817N>T | p.Arg273Cys | p.R273C | O14640 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-BH-A18T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| DVL1 | SNV | Missense_Mutation | novel | c.586G>A | p.Glu196Lys | p.E196K | O14640 | protein_coding | deleterious(0.01) | possibly_damaging(0.593) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| DVL1 | SNV | Missense_Mutation | novel | c.1345N>A | p.Asp449Asn | p.D449N | O14640 | protein_coding | deleterious(0.05) | probably_damaging(0.978) | TCGA-EA-A43B-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| DVL1 | SNV | Missense_Mutation | rs766432002 | c.1324N>A | p.Ala442Thr | p.A442T | O14640 | protein_coding | deleterious(0) | possibly_damaging(0.863) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| DVL1 | SNV | Missense_Mutation | novel | c.595N>G | p.Ser199Gly | p.S199G | O14640 | protein_coding | tolerated(0.29) | benign(0.01) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DVL1 | SNV | Missense_Mutation | c.1061C>T | p.Pro354Leu | p.P354L | O14640 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
| DVL1 | SNV | Missense_Mutation | novel | c.17T>A | p.Ile6Asn | p.I6N | O14640 | protein_coding | deleterious(0) | possibly_damaging(0.659) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| DVL1 | SNV | Missense_Mutation | rs376597258 | c.857G>A | p.Gly286Asp | p.G286D | O14640 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CM-4746-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| DVL1 | SNV | Missense_Mutation | c.1130A>G | p.Tyr377Cys | p.Y377C | O14640 | protein_coding | deleterious(0.01) | probably_damaging(0.949) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |